Evogene Accounts Payable

Evogene (EVGN) currently reports a accounts payable of $460K as of March 2026. That compares with $590K in the prior-year period — down 21.8% year over year. Use the charts on this page to explore Evogene's accounts payable history and peer comparisons.

Evogene's accounts payable decreased from $590K to $460K — a 21.8% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Evogene reported $460K in accounts payable as of March 2026. That compares with $590K in the prior-year period — down 21.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $460K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Evogene, and consider following EVGN for alerts when major investors trade the stock.

Evogene is classified in the Materials sector. On accounts payable, it currently shows $460K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Materials are usually more informative than comparing EVGN with unrelated industries.